Enanta Pharmaceuticals, Inc. · NASDAQ:ENTA
Enanta Pharmaceuticals — Investor Presentation (September 2026)
39 slides from Enanta Pharmaceuticals's investor presentation, Sep 14, 2026
Slide 1: Corporate Presentation
Corporate Presentation September 14, 2026
Slide 2: Forward Looking Statements Disclaimer
Forward Looking Statements Disclaimer This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our research and development programs, our business and the industry in which
Slide 3: Enanta Overview
Enanta Overview Clinical-stage All compounds biotechnology company discovered in dedicated to creating house, leveraging small molecule deep expertise in drugs for virology & medicinal chemistry, drug immunology indications discovery & development 2 products approved with Founded: 1995 STRONG CASH P
Slide 4: Enanta Pipeline
Enanta Pipeline DISEASE TARGET DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 MARKET Virology: Hepatitis C Virus Protease Glecaprevir* Liver Zelicapavir High-Risk Adults N-Protein Respiratory Zelicapavir Pediatrics Virology: Syncytial Virus Respiratory L-Protein EDP-323 (challenge study) 3CL COVID-19
Slide 5: Virology: Respiratory Syncytial Virus
Virology: Respiratory Syncytial Virus
Slide 6: Respiratory Syncytial Virus (RSV)
Respiratory Syncytial Virus (RSV) Causes severe lung infections, including bronchiolitis (infection of small airways in the lungs) and pneumonia. No safe and effective treatments are currently approved. RSV Burden Estimates1 Significant Unmet Need for Antivirals (2024 - 2025 U.S.) • Adult vaccines h
Slide 7: Multi-Billion Dollar Global Market Opportunity for an RSV Antiviral
Multi-Billion Dollar Global Market Opportunity for an RSV Antiviral Up to 4M Addressable Patients with RSV in the United States1 ~4M Additional High-Risk Adults: ~1.3M CKD, IC, T2DM, ONC Multi-Billion $ Global Revenue Potential2 ~$2.6B–3.5B HR3 Adults: • Additional High-Risk Adults ~1.2M CHF, COPD,
Slide 8: RSV Development Goal
RSV Development Goal: Treatment for Patients at High-Risk for Severe RSV Infection Leading portfolio of RSV replication inhibitors with potential for first-in-disease (zelicapavir) and best-in-disease (EDP-323) treatments and ability for combination Age ≥65 years Zelicapavir High-Risk Adult Positive
Slide 9: Zelicapavir (EDP-938): N-Protein Inhibitor for RSV
Zelicapavir (EDP-938): N-Protein Inhibitor for RSV • Only N-inhibitor in clinical development for RSV – Replication inhibitor: shuts down the production of new RSV virions (vs. fusion inhibitors which block viral entry) • Granted Fast Track designation by the FDA • Strong preclinical profile – Nanom
Slide 10: Zelicapavir High-Risk Adult Program: Phase 2b Study Summary
Zelicapavir High-Risk Adult Program: Phase 2b Study Summary • Demonstrated compelling results on multiple • Robust antiviral effect clinically meaningful endpoints measuring different aspects of RSV disease • Well-tolerated, with a favorable safety profile Up to one week improvement in complete Ri
Slide 11: Zelicapavir High-Risk Adult Phase 2b/3 Registrational Study Design
Zelicapavir High-Risk Adult (HR3) Program: Phase 2b/3 Global Registrational Study Design Double-Blind Primary Objective* Inclusion Criteria Treatment Phase • Adult outpatients with Randomized 1:1 Time to complete resolution of RSV* 13 RSV symptoms as measured by RiiQ • Symptom onset within 3 Placebo
Slide 12: Zelicapavir Pediatric Program: First-in-Pediatric Phase Study Summary
Zelicapavir Pediatric Program: First-in-Pediatric Phase 2 Study Summary • Well-tolerated, with favorable safety profile – No adverse events leading to treatment discontinuation or study withdrawal Primary Objectives of Study • Antiviral effect observed for the primary and secondary virology endpoint
Slide 13: Zelicapavir Pediatric Program: Phase 2b Study Design
Zelicapavir Pediatric Program: Phase 2b Study Design Double-Blind Primary Objective Treatment Phase Randomized 1:1 Time to complete symptom Inclusion Criteria resolution as measured by Placebo (QD) RESOLVE-P Trial Design • Pediatric inpatients and 28 Day outpatients with RSV N=150 Follow-up • Sympto
Slide 14: EDP-323: RSV L-Protein Inhibitor
EDP-323: . RSV L-Protein Inhibitor • Direct-acting antiviral targeting the L-protein RSV – Replication inhibitor: shuts down the production of new virions (vs. fusion inhibitors which block viral entry) • Granted Fast Track designation by the FDA • Sub-nanomolar potency against RSV-A and B • Protect
Slide 15: EDP-323: Phase 2a RSV Challenge Study Conclusions
EDP-323: Phase 2a RSV Challenge Study Conclusions • Well-tolerated with safety Viral Load (Log10 PFU/mL) Mean (±SE) profile similar to placebo EDP-323 EDP-323 High Dose Low Dose • Primary and key secondary % AUC Reduction 98.32% 97.26% efficacy endpoints achieved (vs pbo) P-value <0.0001 <0.0001 wit
Slide 16: Immunology
Immunology i: Enanta Pharmaceuticals
Slide 17: Building Enanta's Immunology Portfolio: Focusing on Best-in-Disease Treatments
Building Enanta’s Immunology Portfolio: Focusing on Best-in-Disease Treatments Exploit novel biology to select targets with potential in multiple indications Leverage innovative chemistry to develop best-in-class small molecule drugs Clinical, genetic, or pathway Strong Target Rationale validation t
Slide 18: Immunology Portfolio: Multiple Targets Addressing Type 2 Immune Diseases
Immunology Portfolio: Multiple Targets Addressing Type 2 Immune Diseases KIT MRGPRX2 STAT6 Mast cell activator KIT MRGPRX2 receptor neuropeptides IL-4/13 IL-4/IL-13 mAb antimicrobial peptides xenobiotics IL-4Rα γC/IL-13Rα1 P JAK3/ JAK1 P TYK2 STAT6 STAT6 STAT6 Mast cell P P Inhibition activator P P
Slide 19: Immunology Portfolio: Addressing unmet need in multiple Type 2 immune-driven diseases
Immunology Portfolio: Addressing unmet need in multiple Type 2 immune-driven diseases • Type 2 inflammation is Indications / 2032F Market Potential 1 characterized by overproduction of $>120B Explore Total IL-4, IL-5, IL-13, and IgE which recruits and activates Th2 CD4 TBD* T cells, B cells, mast ce
Slide 20: Chronic Spontaneous Urticaria (CSU): KIT and MRGPRX2 Inhibitor Initial Focus
Chronic Spontaneous Urticaria (CSU): KIT and MRGPRX2 Inhibitor Initial Focus for Clinical Proof of Concept • Severely debilitating, chronic inflammatory skin disease Hives Itch Erythema – Driven by mast cell activation, triggering release of inflammatory mediators1 – Quality of life impacts beyond t
Slide 21: Atopic Dermatitis (AD): STAT6 Inhibitor Initial Focus
Atopic Dermatitis (AD): STAT6 Inhibitor Initial Focus for Clinical Proof of Concept • Chronic dermatological disease characterized by dry, red, inflamed, irritated and itchy skin – Driven by Th2 immune dysregulation1 – Quality of life impacts beyond the skin: limited lifestyle, avoidance of social i
Slide 22: Immunology: KIT Inhibitor
Immunology: KIT Inhibitor i: Enanta Pharmaceuticals
Slide 23: KIT Inhibitors Offer Potential for Differentiated Efficacy
KIT Inhibitors Offer Potential for Differentiated Efficacy • Mast cells: primary driver of inflammation in skin, and implicated in multiple allergic diseases – Urticaria (CSU, CIndU), asthma and others • KIT: well-characterized receptor tyrosine kinase critical for regulating mast cell activity • KI
Slide 24: Goal of Oral KIT Inhibitor Program
Goal of Oral KIT Inhibitor Program: Develop Best-in-Class Treatment for Mast Cell Mediated Diseases • EDP-978 selected as clinical candidate – Inhibits KIT with nanomolar potency in both binding and cellular assays – Demonstrates sub-nanomolar activity in vivo – Highly selective for KIT versus other
Slide 25: EDP-978 Exhibits Potent Inhibition and Good Selectivity of KIT
EDP-978 Exhibits Potent Inhibition and Good Selectivity of KIT In Vitro and In Vivo • Nanomolar inhibition in cellular assays with an • Inhibits SCF-mediated histamine release in mice EC50 of 1.6 – 3.4nM with an EC50 (free drug) of 0.25nM Binding or Cellular Assay* EC50 (nM) KIT Inhibitor SCF Challe
Slide 26: Immunology: STAT6 Inhibitor
Immunology: STAT6 Inhibitor
Slide 27: STAT6 Inhibitors Offer Potential for an "Oral DUPIXENT"
STAT6 Inhibitors Offer Potential for an “Oral DUPIXENT®” • Th2 dysregulation drives allergic and autoimmune diseases including atopic dermatitis and asthma IL-4/13 IL-4/IL-13 mAb – Characterized by IL-4 & IL-13 overproduction IL-4Rα γC/IL-13Rα1 • STAT6: transcription factor responsible for IL-4/IL-1
Slide 28: Goal of Oral STAT6 Inhibitor Program
Goal of Oral STAT6 Inhibitor Program: Develop Best-in-Class Oral STAT6 Inhibitors • EPS-3903 selected as development candidate – Favorable in vitro and in vivo ADME properties supporting once daily dosing – Inhibits STAT6 with nanomolar potency in both binding and cellular assays – Highly selective
Slide 29: EPS-3903 Demonstrates Potent Activity & Good Selectivity
EPS-3903 Demonstrates Potent Activity & Good Selectivity • Nanomolar inhibition in biochemical • No inhibition of other STATs observed in human PBMCs (Kd = 0.4 nM) and cellular assays • >1000x biochemical selectivity for STAT6 over other STATs – Inhibits phosphorylation of STAT6 and STAT6-mediated c
Slide 30: EPS-3903 Results in Complete Inhibition of pSTAT6 in Mouse Model
EPS-3903 Results in Complete Inhibition of pSTAT6 in Mouse Model • In vivo STAT6 target engagement after a single oral dose 24 hours post-oral dose • Rapid, complete and continuous (>90%) inhibition of in IL-4-stimulated phosphorylated STAT6 sustained for 24 hours mouse whole blood 120 % pSTAT6 Indu
Slide 31: EPS-3903 Shows Comparable Efficacy to Dupilumab in HDM Asthma Model
EPS-3903 Shows Comparable Efficacy to Dupilumab in a House Dust Mite (HDM) Challenge Asthma Model • HDM model in transgenic mice expressing 150 Lung pSTAT6 HDM-Challenged 200 BALF Eosinophils HDM-Challenged % of HDM Vehicle Cell number (X104) human IL-4/IL-4Rα triggers allergic airway 150 100 inflam
Slide 32: EPS-3903 Comparable Efficacy to Dupilumab in MC903 Atopic Dermatitis Model
EPS-3903 Demonstrates Comparable Efficacy to Dupilumab in a MC903-Driven Atopic Dermatitis Mouse Model • MC903 model in transgenic mice expressing human IL-4/IL-4Rα triggers TSLP-mediated systemic inflammation with increased B-cell activity EPS-3903 efficacy comparable to dupilumab • >90% inhibition
Slide 33: Immunology: MRGPRX2 Inhibitor
Immunology: MRGPRX2 Inhibitor
Slide 34: MRGPRX2 Inhibitors Offer Potential in Migraine and Other Mast Cell Diseases
MRGPRX2 Inhibitors Offer Potential in Migraine and Other Mast Cell Associated Diseases • MRGPRX2: non-canonical GPCR expressed on mast cells MRGPRX2 • Mast Cells: involved in the pathology of multiple diseases Neuropeptides – Th2 Diseases: urticaria, asthma, AD and others antimicrobial (eg; PACAP) •
Slide 35: Goal of Oral MRGPRX2 Inhibitor Program
Goal of Oral MRGPRX2 Inhibitor Program: Develop Best-in-Class Treatment for Mast Cell Diseases & Migraine • Novel, oral inhibitors of MRGPRX2 being optimized in discovery stage Inhibits Prevents Highly selective Favorable in vitro MRGPRX2 skin mast cell for MRGPRX2 and in vivo ADME with nanomolar ac
Slide 36: Prototype MRGPRX2 Inhibitor Exhibits Potent Inhibition In Vitro and In Vivo
Prototype MRGRPX2 Inhibitor Exhibits Potent Inhibition In Vitro and In Vivo • Potent nanomolar inhibition in cellular • Prevents skin mast cell activation in humanized assays with an EC50 of 1 – 2nM MRGPRX2 mice1 MRGPRX2 Inhibitor MRGPRX2 Agonist Cortistatin-14* • Preferred non-competitive mechanism
Slide 37: Prototype MRGPRX2 Inhibitor Demonstrates Potent Activity Across Multiple Agonists
Prototype MRGRPX2 Inhibitor Demonstrates Potent Activity Across Multiple Agonists Antimicrobial Exogeneous • Potent inhibition of degranulation in LAD2 cells across Peptides Icatibant endogenous and exogenous MRGPRX2 ligands LL-37 Chlorpromazine Vancomycin Neuropeptides Peptide β-hexosaminidase Cort
Slide 38: 2026 Key Catalysts
2026 Key Catalysts Respiratory Syncytial Virus FDA End-of-Phase 2 meeting on adult pivotal study design & registration path in 2Q 2026 Virology Initiate Phase 2b study of zelicapavir in pediatric patients in 3Q 2026 Initiate Phase 2b/3 study of zelicapavir in high-risk adults in 4Q 2026 Explore
Slide 39: www.enanta.com
Ei: Enanta Pharmaceuticals www.enanta.com
Enanta Pharmaceuticals — Investor Presentation (September 2026) on 6ix